Tocagen Inc. priced its underwritten public offering of 3 million common shares at $10 apiece.
The clinical-stage, cancer-selective gene therapy company expects to raise gross proceeds of about $30 million from the offering, before deducting the underwriting discounts and commissions and other offering expenses.
Underwriters have a 30-day option to purchase up to an additional 450,000 common shares at the public offering price, less the underwriting discounts and commissions.
The offering is expected to close on or about Dec. 17, subject to customary closing conditions.
Citigroup and Leerink Partners are acting as joint book-running managers for the offering.